Cabotegravir

Cabotegravir (pronounced: ka-bo-te-gra-vir) is an antiretroviral medication used in the treatment and prevention of HIV/AIDS. It is developed by ViiV Healthcare, a specialist HIV company majority owned by GlaxoSmithKline.

Etymology

The name "Cabotegravir" is derived from the chemical structure of the drug. The "Cab" part of the name refers to the carbonyl group in the chemical structure, the "teg" refers to the tetrazole group, and the "vir" is a common suffix for antiviral medications.

Pharmacology

Cabotegravir is a type of drug known as an integrase inhibitor. It works by blocking the action of an enzyme called integrase, which the HIV virus uses to insert its genetic material into human cells. By blocking this action, Cabotegravir prevents the virus from replicating and spreading.

Usage

Cabotegravir is used in combination with other antiretroviral medications to treat HIV. It is also used as a pre-exposure prophylaxis (PrEP) to prevent HIV infection in people at high risk. The drug is administered as a long-acting injectable formulation, which is given once every two months.

Side Effects

Common side effects of Cabotegravir include headache, fever, fatigue, and injection site reactions. Serious side effects may include liver problems and allergic reactions.

Related Terms

• Antiretroviral therapy
• Integrase inhibitor
• Pre-exposure prophylaxis
• HIV/AIDS

External links

• Medical encyclopedia article on Cabotegravir
• Wikipedia's article - Cabotegravir

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski